In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 2, 2000, Pages 470-472

  Meletiadis, Joseph ^a   Mouton, Johan W ^b   Rodriguez Tudela, Juan L ^c   Meis, Jacques F G M ^a   Verweij, Paul E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [4 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 1 PIPERAZINYL]PHENYL] 2,4 DIHYDRO 2 [4 (TRIFLUOROMETHOXY)BENZYL] 1,2,4 TRIAZOL 3 ONE; AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; TERBINAFINE; VORICONAZOLE;

ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENCY; DRUG POTENTIATION; INCUBATION TIME; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SCEDOSPORIUM; SCEDOSPORIUM PROLIFICANS; STRAIN DIFFERENCE;

ASCOMYCOTA; DRUG INTERACTIONS; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES;

EID: 0033978876     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.2.470-472.2000     Document Type: Article

References (16)

1. Barchiesi, F., L. Falconi Di Francesco, and G. Scalise. 1997. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob. Agents Chemother. 41:1812-1814.
2. Berenguer, J., J. L. Rodriguez-Tudela, C. Richard, M. Alvarez, M. A. Sanz, L. Gaztelurrutia, J. Ayats, and J. V. Martinez-Suarez. 1997. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature. Scedosporium Prolificans Spanish Study Group. Medicine (Baltimore) 76:256-265.
3. Cuenca-Estrella, M., B. Ruiz-Díez, J. V. Martínez-Suárez, A. Monzón, and J. L. Rodríguez-Tudela. 1999. Comparative in vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum. J. Antimicrob. Chemother. 43:149-151.
4. Del Poeta, M., W. A. Schell, and J. R. Perfect. 1997. In vitro activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicroh. Agents Chemother. 41:1835-1836.
5. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
6. Garcia-Arata, M. I., M. J. Otero, M. Zomeno, M. A. de la Figuera, M. C. de las Cuevas, and M. Lopez-Brea. 1996. Scedosporium apiospermum pneumonia after autologous hone marrow transplantation. Eur. J. Clin. Microbiol. Infect. Dis. 15:600-603.
7. Hallander, H. O., K. Dornbusch, L. Gezelius, K. Jacobson, and I. Karlsson. 1982. Synergism between aminoglycosides and cephalosporins with antipseudomonal activity: interaction index and killing curve method. Antimicrob. Agents Chemother. 22:743-752.
8. Jahn, B., A. Stuben, and S. Bhakdi. 1996. Colorimetric susceptibility testing for Aspergillus fumigatus: comparison of menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide and Alamar blue tests. J. Clin. Microbiol. 34:2039-2041.
9. Johnson, E. M., A. Szekely, and D. W. Warnock. 1999. In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens. Antimicrob. Agents Chemother. 43:1260-1263.
10. Kovarik, J. M., E. A. Mueller, H. Zehender, J. Denouël, H. Caplan, and L. Millerioux. 1995. Multiple-dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob. Agents Chemother. 39:2738-2741.
11. National Committee for Clinical Laboratory Standards. 1998. Reference method for broth dilution antifungal susceptibility testing of conidium-forming fungi. Proposed standard M38-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
12. Patterson, T. F., J. Peters, S. M. Levine, A. Anzuelo, C. L. Bryan, E. Y. Sako, O. L. Miller, J. H. Calhoon, and M. G. Rinaldi. 1996. Systemic availability of itraconazole in lung transplantation. Antimicrob. Agents Chemother. 40: 2217-2220.
13. Salkin, I. F., M. R. McGinnis, M. J. Dykstra, and M. G. Rinaldi. 1988. Scedosporium inflatum, an emerging pathogen. J. Clin. Microbiol. 26:498-503.
14. Shenep, J. L., B. K. English, L. Kaufman, T. A. Pearson, J. W. Thompson, R. A. Kaufman, G. Frisch, and M. G. Rinaldi. 1998. Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child. Clin. Infect. Dis. 27:1388-1393.
15. Verweij, P. E., N. J. Cox, and J. F. Meis. 1997. Oral terbinafine for treatment of pulmonary Pseudallescheria boydii infection refractory to itraconazole therapy. Eur. J. Clin. Microhiol. Infect. Dis. 16:26-28.
16. Walsh, T. J., J. Peter, D. A. McGough, A. W. Fothergill, M. G. Rinaldi, and P. A. Pizzo. 1995. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob. Agents Chemother. 39:1361-1364.